Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis
Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis. // Biochimica et Biophysica Acta: Molecular Cell Research. – URL: https://www.sciencedirect.com/science/article/pii/S0167488926001230?dgcid=rss_sd_all
Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis. Biochimica et Biophysica Acta: Molecular Cell Research. https://www.sciencedirect.com/science/article/pii/S0167488926001230?dgcid=rss_sd_all
“Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis.” Biochimica et Biophysica Acta: Molecular Cell Research.
@article{article1540,
title = {Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis},
journal = {Biochimica et Biophysica Acta: Molecular Cell Research},
url = {https://www.sciencedirect.com/science/article/pii/S0167488926001230?dgcid=rss_sd_all}
}
Nature Cell Biology, Published online: 16 November 2026; doi:10.1038/s41556-026-02154-w Author Correction: Protein quality control through endoplasmic reticulum-associated degradation maintains haematopoietic stem cell identity and...
Resilience—A Concept Toward an Actionable Clinical Approach to AgingVanessa Matos Gonçalves,
Ekaterina Maevskaia,
Moon‐Ju Kim,
Adrian Molière,
Sijie Ji,
Ferdinand von Meyenn,
Grzegorz Filip Sarek,
Elisabeth Roider,
Catherine R. Jutzeler,
Edouard Battegay,
René M. Rossi,
Collin Y. Ewald,
Simon Annaheim,
Jörg Goldhahn,
Wei Gao,
Noé BrasierAging Cell
· Cell Biology
· 2026-11-14